Eikon Therapeutics

Eikon Therapeutics (Ticker: EIKN US) develops medicines, with an initial focus on oncology. EIK1001 is described as a mid-to-late-stage drug candidate, but its intended use and specific clinical stage are not stated. Since its founding in 2019, the company has reportedly raised more than $1.00 billion from private investors, including Lux Capital and Foresite Capital. IPO proceeds are intended to advance the clinical pipeline.

The scheduled listing date on Nasdaq was February 5, 2026. The proposed offering comprises 17,648,000 shares at an indicative price range of $16.00–18.00 per share. At the indicative range midpoint, the base offering would represent $300.02 million in gross proceeds, excluding any unexercised over-allotment.

J.P. Morgan, Morgan Stanley, BofA Securities, and Cantor are the bookrunning group.